Royalty Pharma Plc Revenue Growth Rates (RPRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Royalty Pharma Plc  (NASDAQ: RPRX)
 

RPRX's Revenue Growth by Quarter and Year

Royalty Pharma Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RPRX/growth
https://api.csimarket.com/api/v1/companies/RPRX/fundamentals
https://api.csimarket.com/api/v1/companies/RPRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
RPRX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 690.10
2nd Quarter June 674.14
1st Quarter March 630.58
FY 1,994.82

RPRXs Annual Revenue
Royalty Pharma Plc's Revenue in the fiscal year 2025 $ 2,378.19 millions
Royalty Pharma Plc's Revenue in the fiscal year 2024 $ 2,263.58 millions
Royalty Pharma Plc's Revenue in the fiscal year 2023 $ 2,354.55 millions
Royalty Pharma Plc's Revenue in the fiscal year 2022 $ 2,237.22 millions
Royalty Pharma Plc's Revenue in the fiscal year 2021 $ 2,289.46 millions




RPRX Revenue third quarter 2026 Y/Y Growth Comment
Royalty Pharma Plc reported Revenue increase of 13.26% year on year in the third quarter 2026, to $ 690.10 millions, this is lower than Royalty Pharma Plc's recent average Revenue surge of 156.85%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Revenue growth. While Royalty Pharma Plc' s Revenue growth of 13.26% ranks overall at the positon no. 1206 in the third quarter 2026.


RPRX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 13.26 %
2nd Quarter June 16.5 %
1st Quarter March 10.97 %
FY   -

Financial Statements
Royalty Pharma Plc's third quarter 2026 Revenue $ 690.10 millions RPRX's Income Statement
Royalty Pharma Plc's third quarter 2025 Revenue $ 609.29 millions Quarterly RPRX's Income Statement


RPRX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.37 %
2nd Quarter June 6.91 %
1st Quarter March 1.38 %
FY (Year on Year)   -


Back to RPRX Growth rate Comparisons >> Back to RPRX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #221
Overall #1206

Revenue Y/Y Growth Statistics
High Average Low
2940 % 156.85 % -100 %
(Dec 31 2020)   (Sep 30 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #221
Overall #1206
Revenue Y/Y Growth Statistics
High Average Low
2940 % 156.85 % -100 %
(Dec 31 2020)   (Sep 30 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Royalty Pharma Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4242.86 % 104.4 % -100 %
(Sep 30 2017)  


RPRX's III. Quarter Q/Q Revenue Comment
Royalty Pharma Plc achieved in the III. Quarter 2026 below company average Revenue growth of 2.37% quarter on quarter, to $ 690.10 millions.

Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Royalty Pharma Plc's Revenue growth quarter on quarter, overall rank is 1014.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #151
Overall #1014
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #64
Healthcare Sector #151
Overall #1014
Revenue Q/Q Growth Statistics
High Average Low
4242.86 % 104.4 % -100 %
(Sep 30 2017)  


RPRX's III. Quarter Q/Q Revenue Comment
Royalty Pharma Plc achieved in the III. Quarter 2026 below company average Revenue growth of 2.37% quarter on quarter, to $ 690.10 millions.

Within Major Pharmaceutical Preparations industry 63 other companies have achieved higher Revenue quarter on quarter growth. While Royalty Pharma Plc's Revenue growth quarter on quarter, overall rank is 1014.


Royalty Pharma Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 2,536.00
Y / Y Revenue Growth (TTM) 10.01 %
Year on Year Revenue Growth Overall Ranking # 2274
Seqeuential Revenue Change (TTM) 3.91 %
Seq. Revenue Growth (TTM) Overall Ranking # 2406


Cumulative Revenue growth Comment
Although Royalty Pharma Plc's Annual Revenue growth year on year were below company's average 309732.79% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.01% year on year, from 7.8% in Mar 31 2026.

In the Healthcare sector 332 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1064 to 2274.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 333
Overall # 2274

Revenue TTM Y/Y Growth Statistics
High Average Low
7318358.62 %
 309732.79 %
-40 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 114
Sector # 351
S&P 500 # 2406
Cumulative Revenue growth Comment
Although Royalty Pharma Plc's Annual Revenue growth year on year were below company's average 309732.79% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 10.01% year on year, from 7.8% in Mar 31 2026.

In the Healthcare sector 332 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1064 to 2274.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 114
Healthcare Sector # 333
Overall # 2274

Revenue TTM Y/Y Growth Statistics
High Average Low
7318358.62 %
309732.79 %
-40 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 114
Sector # 351
S&P 500 # 2406




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RPRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Atrium Therapeutics Inc 22.81%$ 22.814 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions


About Royalty Pharma Plc Revenue Growth Rates (RPRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.